GC Green Cross Reports 1st Quarter Operating Profit of 11.7 Billion Won Driven by Aliglo Sales

Thanks to the explosive growth of its blood product Aliglo, GC Green Cross reported a nearly 50% increase in operating profit for the first quarter of this year. The company anticipates that the quarterly sales growth of Aliglo will continue throughout the year, especially after the U.S. customs policy announced in April exempted plasma-derived products from tariffs, significantly alleviating uncertainties in the local market.

On May 8, GC Green Cross announced that its consolidated financial statements for the first quarter showed sales of 435.5 billion won and an operating profit of 11.7 billion won. Sales increased by 13.5% compared to the same period last year, while operating profit rose by 46.3%. The net profit was reported at 20.1 billion won.

Notably, Aliglo's sales for the first quarter reached 34.9 billion won, nearly quadrupling compared to the same period last year.

Sales by business segment included 114.9 billion won from plasma-derived products, 81.6 billion won from prescription drugs, 56.8 billion won from vaccines, and 32.4 billion won from over-the-counter medicines and consumer healthcare.

In the U.S., the company's subsidiary ABO Plasma recently received FDA approval for its plasma center in Laredo, Texas, and is planning to open a new center in Eagle Pass within the year. The recent U.S. customs policy, which includes plasma-derived products in the tariff exemption, has also resolved uncertainties related to this business.

By subsidiary, GC Cell reported 37.4 billion won in sales, while GC Green Cross MS generated 23.6 billion won. GC Green Cross Wellbeing achieved sales of 49.1 billion won, although it will be excluded from consolidated results starting in the second quarter due to a stake sale on March 31.

Market analysts believe that GC Green Cross, which recorded a significant loss of over 100 billion won in the fourth quarter of last year, will continue to improve its performance in the first quarter, driven by stable growth in key products like Aliglo.

A representative from GC Green Cross stated, "We will continue to expand our market dominance through the stabilization of plasma center operations and the opening of additional centers."